Kumar et al. showed that CARM1 inhibition increased tumor-infiltrating CD8+ T cell numbers, promoted granzyme B and IFN-γ expression, and Ki-67 marker proliferation, which facilitated a stronger tumor-killing capacity in CD8+ T cells, suggesting CARM1 inhibition enhanced CD8+ T proliferation and cytokine production (79). Here, CD8A is linked to neoplasm.